Having tools to detect colorectal cancer early is good. Also having tools to identify those at high risk of developing colorectal cancer is better. Doing so non-invasively is the best.
Due primarily to the inconvenience and invasive nature of colonoscopies, over 40% of patients fail to get screened. As a result, colorectal cancer remains the third most common type of cancer in the US and inflicts an unacceptably high mortality rate. This is the primary challenge that Geneoscopy is tackling today.
With the highly publicized launch of RNA-based COVID-19 vaccines, one could say RNA is having its moment. At Geneoscopy, we believe this moment is overdue. Moreover, the coronavirus pandemic has made the clinical community and even the general public acutely aware of the importance of test sensitivity. In a clinical study, when compared against the gold-standard colonoscopy, our RNA-based platform demonstrated better sensitivity data in detecting advanced adenomas and colorectal cancer than that generated by any other available non-invasive test in their respective clinical studies. Finally, the pandemic has increased the appetite for at-home testing due to its convenience. Our platform will enable sample collection in the convenience of patients’ homes, further reducing the barriers to colorectal cancer screening.
Geneoscopy is developing a broad portfolio of non-invasive gastrointestinal-related diagnostics and is executing robust trials for FDA approval that will help ensure the safety and efficacy of these tests. Geneoscopy has initiated the CRC-PREVENT trial, a 10,000-patient study to evaluate the performance of its RNA-FIT stool test to detect colorectal cancer and advanced adenomas. Interested in advancing science? See if you’re eligible to participate.